What is the study about?
The enviva study is a Phase 2 clinical research study. The enviva study lasts about 19 weeks and includes a Screening Period, Baseline Period, Dosing Period, and Follow-up Period.
The goal of the enviva study is to explore the effects of an investigational drug on the symptoms of irritable bowel syndrome with predominant diarrhea (IBS-D). Researchers are studying how the investigational drug may help ease unpleasant symptoms, such as abdominal pain, bloating, and stool consistency.
What is the investigational drug?
CIN-103 is the investigational drug being researched in this study. It was designed to work differently from approved IBS-D treatment options. The investigational drug is a new formulation of a gastrointestinal drug called phloroglucinol, which relieves painful spasms within the GI tract. The investigational drug is designed to work similarly to help relieve symptoms of pain, cramping, and diarrhea.
Note: phloroglucinol is not approved by regulatory agencies in all countries.
Criteria:If you answer yes to the following questions, you may be eligible:
Are you an adult male or female 18 years of age or older?
Have you been diagnosed with IBS-D?
Do you expect no changes to your lifestyle, exercise routine, and/or diet during study participation?
Are you willing to complete a daily eDiary?